Sign In
Buy PHGE
$0.184
-0.0046 (-2.44%)
At Close: Jul 31, 2026
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
06:30am, Wednesday, 27'th Mar 2024
CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and en
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
06:30am, Monday, 18'th Mar 2024
Acquisition creates leading phage therapy company with an advanced pipeline that includes two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) pati
Shareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage Therapeutics
03:45am, Thursday, 07'th Mar 2024
MILWAUKEE , March 7, 2024 /PRNewswire/ -- Ademi LLP is investigating BiomX (NYSE American: PHGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Adaptive P
Why Is BiomX (PHGE) Stock Up 147% Today?
11:52am, Wednesday, 06'th Mar 2024
BiomX (NYSEMKT: PHGE ) stock is rocketing higher on Wednesday after announcing merger plans with privately-held clinical-stage biotechnology company Adaptive Phage Therapeutics. This will have the cli
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
07:30am, Wednesday, 06'th Mar 2024
Acquisition will create phage therapy company with an advanced pipeline with two P hase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis ( “ CF ” ) patients and
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage thera
BiomX (PHGE) Reports Positive Pulmonary Infection Treatment Data
06:46am, Monday, 04'th Dec 2023
BiomX's (PHGE) BX004 showcases an impressive 14% conversion to a negative P. aeruginosa sputum culture at the end of treatment.
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and eng
BX004 showed clinically meaningful improvement in pulmonary function as measured in FEV1 1 and C ystic F ibrosis Questionnaire - R evised (CFQ-R) respiratory domain in a predefined subgroup of patient
BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day
07:43am, Thursday, 23'rd Nov 2023
BiomX announced positive results from Part 1 of its Phase 1b/2a study for its novel phage cocktail, BX004, treating chronic pulmonary infections caused by P. aeruginosa bacteria in Cystic Fibrosis. Pa
BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
06:30am, Tuesday, 14'th Nov 2023
Analysis of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and eng
BiomX Announces the Appointment of Edward L. Williams to its Board of Directors
08:00am, Wednesday, 18'th Oct 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapi
BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023
04:30pm, Wednesday, 02'nd Aug 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and eng
BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC)
03:00am, Wednesday, 31'st May 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engi
